ZA947782B - Stable protein: Phospholipid compositions and methods - Google Patents

Stable protein: Phospholipid compositions and methods

Info

Publication number
ZA947782B
ZA947782B ZA947782A ZA947782A ZA947782B ZA 947782 B ZA947782 B ZA 947782B ZA 947782 A ZA947782 A ZA 947782A ZA 947782 A ZA947782 A ZA 947782A ZA 947782 B ZA947782 B ZA 947782B
Authority
ZA
South Africa
Prior art keywords
protein
methods
compositions
stable protein
phospholipid compositions
Prior art date
Application number
ZA947782A
Other languages
English (en)
Inventor
David Collins
Younsik Cha
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA947782B publication Critical patent/ZA947782B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA947782A 1993-10-06 1994-10-05 Stable protein: Phospholipid compositions and methods ZA947782B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13241393A 1993-10-06 1993-10-06

Publications (1)

Publication Number Publication Date
ZA947782B true ZA947782B (en) 1995-05-17

Family

ID=22453938

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA947782A ZA947782B (en) 1993-10-06 1994-10-05 Stable protein: Phospholipid compositions and methods

Country Status (21)

Country Link
EP (1) EP0671905B1 (xx)
JP (1) JP2852127B2 (xx)
KR (1) KR100372006B1 (xx)
CN (1) CN1206982C (xx)
AT (1) ATE222752T1 (xx)
AU (1) AU683698B2 (xx)
CA (1) CA2150939C (xx)
CZ (1) CZ290029B6 (xx)
DE (1) DE69431236T2 (xx)
DK (1) DK0671905T3 (xx)
ES (1) ES2184768T3 (xx)
FI (1) FI116271B (xx)
HK (1) HK1010341A1 (xx)
HU (1) HUT72326A (xx)
IL (1) IL111170A (xx)
NO (1) NO314064B1 (xx)
NZ (1) NZ274705A (xx)
PT (1) PT671905E (xx)
RU (1) RU2119791C1 (xx)
WO (1) WO1995009611A2 (xx)
ZA (1) ZA947782B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP2259768B1 (en) 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
SG11201407812SA (en) * 2012-05-31 2014-12-30 Agency Science Tech & Res Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
EP3135297A4 (en) * 2014-04-04 2018-02-07 Osaka University Drug delivery promoter containing substance for activating lysophospholipid receptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4208527A1 (de) * 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法

Also Published As

Publication number Publication date
FI952738A0 (fi) 1995-06-05
WO1995009611A2 (en) 1995-04-13
FI116271B (fi) 2005-10-31
JPH08505403A (ja) 1996-06-11
CN1117266A (zh) 1996-02-21
FI952738A (fi) 1995-07-31
CA2150939A1 (en) 1995-04-13
CA2150939C (en) 2001-05-01
KR960700042A (ko) 1996-01-19
HUT72326A (en) 1996-04-29
JP2852127B2 (ja) 1999-01-27
AU683698B2 (en) 1997-11-20
KR100372006B1 (ko) 2003-07-18
DE69431236D1 (de) 2002-10-02
CN1206982C (zh) 2005-06-22
RU2119791C1 (ru) 1998-10-10
IL111170A (en) 1999-11-30
AU7923994A (en) 1995-05-01
EP0671905B1 (en) 2002-08-28
NZ274705A (en) 1997-12-19
PT671905E (pt) 2002-12-31
WO1995009611A3 (en) 1995-06-22
DK0671905T3 (da) 2002-10-07
DE69431236T2 (de) 2003-01-02
IL111170A0 (en) 1994-12-29
NO314064B1 (no) 2003-01-27
HK1010341A1 (en) 1999-06-17
EP0671905A1 (en) 1995-09-20
CZ143895A3 (en) 1996-01-17
HU9502053D0 (en) 1995-10-30
ES2184768T3 (es) 2003-04-16
CZ290029B6 (cs) 2002-05-15
NO952210D0 (no) 1995-06-02
ATE222752T1 (de) 2002-09-15
NO952210L (no) 1995-08-04

Similar Documents

Publication Publication Date Title
IL117690A0 (en) Stable protein: phospholipid compositions and methods
ES8507573A1 (es) Procedimiento para la fabricacion de fracciones de acido hialuronico
AU5018693A (en) Sustained-release protein formulations
AU1162099A (en) Prolamin-plant polar lipid combination, preparation method and applications
WO1997010851A3 (en) Nucleic acid delivery vehicle
CA2039491A1 (en) Stable compositions for parenteral administration and method of making same
IL122486A (en) Process for making liposome preparation
CA2002540A1 (fr) Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees procede de preparation du facteur ix et produits obtenus correspondants
AU3530997A (en) Use of complex lipids as stabilising additives to pharmaceutical preparations of digestive enzyme mixtures
ES2077904T3 (es) Obtencion y uso de preparados estables de liposomas en forma de pequeñas particulas.
IL111170A0 (en) Stable protein: phospholipid compositions and methods
RU95117866A (ru) Фосфолипидные композиции и способ их получения
DE69520231D1 (de) Liposomzubereitungen enthaltend hybrid-interferon